Development of the first metabolite-based LC-MS(n) urine drug screening procedure-exemplified for antidepressants.
about
Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazinesKetamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSnIdentification of small molecules using accurate mass MS/MS searchEvaluation of the sensitivity of the 'Wiley registry of tandem mass spectral data, MSforID' with MS/MS data of the 'NIST/NIH/EPA mass spectral library'.Evaluation of the performance of a tandem mass spectral library with mass spectral data extracted from literature.Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept.Towards a universal LC-MS screening procedure - can an LIT LC-MS(n) screening approach and reference library be used on a quadrupole-LIT hybrid instrument?On the inter-instrument and the inter-laboratory transferability of a tandem mass spectral reference library. 3. Focus on ion trap and upfront CID.Towards a full reference library of MS(n) spectra. II: A perspective from the library of pesticide spectra extracted from the literature/Internet.2-methiopropamine, a thiophene analogue of methamphetamine: studies on its metabolism and detectability in the rat and human using GC-MS and LC-(HR)-MS techniques.A high-sensitivity ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry (UHPLC-HR-TOFMS) method for screening synthetic cannabinoids and other drugs of abuse in urine.The in vivo and in vitro metabolism and the detectability in urine of 3',4'-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenone-type designer drug, studied by GC-MS and LC-MS(n.).Qualitative metabolism assessment and toxicological detection of xylazine, a veterinary tranquilizer and drug of abuse, in rat and human urine using GC-MS, LC-MSn, and LC-HR-MSn.Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-HR-MS/MS.Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MS(n) techniques.Lefetamine, a controlled drug and pharmaceutical lead of new designer drugs: synthesis, metabolism, and detectability in urine and human liver preparations using GC-MS, LC-MS(n), and LC-high resolution-MS/MS.Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MSn, and LC-HR-MS-MS.Diphenidine, a new psychoactive substance: metabolic fate elucidated with rat urine and human liver preparations and detectability in urine using GC-MS, LC-MSn , and LC-HR-MSn.Applying 'Sequential Windowed Acquisition of All Theoretical Fragment Ion Mass Spectra' (SWATH) for systematic toxicological analysis with liquid chromatography-high-resolution tandem mass spectrometry.Compound identification in forensic toxicological analysis with untargeted LC-MS-based techniques.Current status of hyphenated mass spectrometry in studies of the metabolism of drugs of abuse, including doping agents.Aspects of matrix effects in applications of liquid chromatography-mass spectrometry to forensic and clinical toxicology--a review.Recent developments in urinalysis of metabolites of new psychoactive substances using LC-MS.Power of Orbitrap-based LC-high resolution-MS/MS for comprehensive drug testing in urine with or without conjugate cleavage or using dried urine spots after on-spot cleavage in comparison to established LC-MSn or GC-MS procedures.Multiple stage MS in analysis of plasma, serum, urine and in vitro samples relevant to clinical and forensic toxicology.New Psychoactive Substances 3-Methoxyphencyclidine (3-MeO-PCP) and 3-Methoxyrolicyclidine (3-MeO-PCPy): Metabolic Fate Elucidated with Rat Urine and Human Liver Preparations and their Detectability in Urine by GC-MS, "LC-(High Resolution)-MSn" and "Case report of accidental poisoning with the tranquilizer xylazine and the anesthetic ketamine confirmed by qualitative and quantitative toxicological analysis using GC-MS and LC-MS(n.).The (un)certainty of selectivity in liquid chromatography tandem mass spectrometry.Studies on the metabolism and detectability of the emerging drug of abuse diphenyl-2-pyrrolidinemethanol (D2PM) in rat urine using GC-MS and LC-HR-MS/MS.Characterization of chemical-induced sterile inflammation in vitro: application of the model compound ketoconazole in a human hepatic co-culture system.Development and validation of an ultrahigh performance liquid chromatography-high resolution tandem mass spectrometry quantification method for hypoglycin A and methylene cyclopropyl acetic acid carnitine in horse serum in cases of atypical myopathyDevelopment and validation of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) procedure for screening of urine specimens for 100 analytes relevant in drug-facilitated crime (DFC).Dimethocaine, a synthetic cocaine analogue: studies on its in-vivo metabolism and its detectability in urine by means of a rat model and liquid chromatography-linear ion-trap (high-resolution) mass spectrometry.Behavioral and neurochemical characterization of kratom (Mitragyna speciosa) extract.Qualitative studies on the metabolism and the toxicological detection of the fentanyl-derived designer drugs 3-methylfentanyl and isofentanyl in rats using liquid chromatography-linear ion trap-mass spectrometry (LC-MS(n)).A multi-analyte approach to help in assessing the severity of acute poisonings - Development and validation of a fast LC-MS/MS quantification approach for 45 drugs and their relevant metabolites with one-point calibration.Metabolism of the tryptamine-derived new psychoactive substances 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT and their detectability in urine studied by GC-MS, LC-MSn , and LC-HR-MS/MS.Assessment of maternal drug intake by urinary bio monitoring during pregnancy and postpartally until the third perinatal year.Metabolic fate of desomorphine elucidated using rat urine, pooled human liver preparations, and human hepatocyte cultures as well as its detectability using standard urine screening approaches.Studies on the metabolism and the detectability of 4-methyl-amphetamine and its isomers 2-methyl-amphetamine and 3-methyl-amphetamine in rat urine using GC-MS and LC-(high-resolution)-MSn.
P2860
Q24631675-009DA6B0-A99A-49E8-A15D-91E16CBAB934Q28292983-8A151215-D4E3-4505-ABC7-EA17B4CAAB82Q29994570-7FA31C91-9D00-4A9B-A3A5-21EB78ABE686Q30616522-1FB3AFA9-51D1-4F83-9812-D4A8DA8EFE75Q33452095-8F95C7FE-25AE-44E2-A497-E9473DC9F5DCQ33887048-3148B6F5-A0E9-45E9-8DC8-30E706C8E29DQ34142688-1E209614-9C16-4F33-8C3E-4814B55737C1Q34167752-DDA3FF29-64F7-4BC6-AD30-8541D620EF8DQ34216776-50D5ABC3-A565-499F-B27E-776298859C62Q34325128-461F9676-C6AD-46F8-B676-46260887179CQ34364856-5164AE00-0B54-482E-8990-99302FF9F338Q34377572-7A6DDD57-A1F9-4E45-BEF8-C8CC04888965Q34378886-F47E7BA1-C9D6-4B60-88CC-5E2B88211B23Q34408021-353D4DF5-93E0-4ED7-8B99-2C07BE199F5DQ34451894-5F07CB5F-A4FA-4D4D-8889-D2F822D7A33EQ34457560-608033A8-1F71-4DA5-9E4A-63562D34EDD7Q34490537-F6C5BC8B-9C18-4C02-A287-B00CBFCF95E9Q34510789-D40E2C6E-3C2F-49FD-80FA-A97E10DDB8CBQ35389892-F1166704-7898-40B2-A69F-43E7CC428C77Q35840290-D7B7BAF2-ADEB-4A33-AC2B-2EE0337909C8Q37922114-BCE86C09-794F-45AD-9E19-0EA304D98251Q38006891-FA7A0F4E-2EDF-4B7B-9F18-50863F27B2BEQ38260819-96ED900A-BE7D-43B1-A9C2-AE8A2C51A3B1Q38654007-35163B22-6C5D-4FC7-B13E-77C73BD13771Q38754171-34573CEA-759F-4697-865C-1665B0D6CF08Q39272650-5C3965A3-58FA-4133-A7C6-D9565CCBA5A0Q43878945-B89DC4EC-04E4-4879-85B3-1B0D996BBD02Q44561200-8C2994C1-CCF2-40BA-8AF5-610AC92B11C0Q44806049-4AE911DB-28B6-40F7-BC12-4407C2FF0868Q46581797-A4ED4CF8-4FAE-4EC0-99BA-2DBEC2CF89AFQ47392689-BEF779C4-7289-46C9-B9E7-3007419E3301Q47872307-AA9D1BCF-9B98-49DE-A85C-9FAA5D5699F7Q47921568-B86C114B-FAB5-4EF0-B542-F77D7E354756Q48000594-3DAA7537-291F-4155-AFC3-557D72031D47Q48216283-05010CF9-82C6-42B7-B6D4-98BD0D708688Q48289328-216A6BA9-9BEC-4673-A5E6-78736C45F64DQ48362650-4C0C0089-D5A5-47D1-B8BA-A4A2C82E1924Q50949045-936E6191-1883-452D-AFC4-BC6E63F20CBDQ51271242-07D133A2-292D-4690-B080-9859E188400EQ52303950-2EED2901-C77B-4729-9C43-C4CA700F8923
P2860
Development of the first metabolite-based LC-MS(n) urine drug screening procedure-exemplified for antidepressants.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Development of the first metab ...... emplified for antidepressants.
@ast
Development of the first metab ...... emplified for antidepressants.
@en
type
label
Development of the first metab ...... emplified for antidepressants.
@ast
Development of the first metab ...... emplified for antidepressants.
@en
prefLabel
Development of the first metab ...... emplified for antidepressants.
@ast
Development of the first metab ...... emplified for antidepressants.
@en
P2093
P2860
P1476
Development of the first metab ...... xemplified for antidepressants
@en
P2093
Armin A Weber
Daniela Remane
Dirk K Wissenbach
Markus R Meyer
P2860
P2888
P356
10.1007/S00216-010-4398-9
P407
P577
2010-11-16T00:00:00Z